Notably, a recent study demonstrated that Ganoderic acid D overcomes gemcitabine resistance by promoting the degradation of HIF-1α driven by MDM2, which leads to a reduction in glycolysis in triple-negative breast cancer cells (Luo et al., 2024). This evidence concerns the gene MDM2 and triple-negative breast carcinoma.